![](https://investorshub.advfn.com/uicon/220347.png?cb=1693474201)
Tuesday, October 31, 2017 8:51:36 AM
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12347628
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Effective October 23, 2017 we changed our Company’s name from Heatwurx, Inc. to Processa Pharmaceuticals, Inc. by filing an Amendment to Fourth Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware. A copy of the Certificate of Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K.
On October 23, 2017 our board of directors authorized and our shareholders, by written consent, approved a reverse stock split (“ Reverse Split ”) pursuant to which each seven (7) issued and outstanding shares of our common stock will be combined and turned into one (1) share of our common stock rounded up to the next whole share, as of that date. We subsequently submitted an application to the Financial Industry Regulatory Association [FINRA] whereby we requested formal approval to (i) change our name from Heatwurx, Inc. to Processa Pharmaceuticals, Inc., and (ii) implement our Reverse Split in our trading markets. As previously disclosed, following our acquisition of assets of Promet Therapeutics, LLC, FINRA approved the change of our trading symbol from “HUWX” to “PCSA”. Please see our Current Report on Form 8-K, as amended, filed on October 12, 2017 with the Securities and Exchange Commission.
Recent PCSA News
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 06/11/2024 06:19:42 PM
- Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer • GlobeNewswire Inc. • 06/11/2024 12:20:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/29/2024 04:15:13 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/28/2024 08:49:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:13:45 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/21/2024 08:10:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:16:05 PM
- Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference • GlobeNewswire Inc. • 03/28/2024 12:15:00 PM
- Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting • GlobeNewswire Inc. • 03/25/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:25:13 PM
- Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/21/2024 01:15:00 PM
- Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference • GlobeNewswire Inc. • 02/14/2024 06:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 01:30:35 PM
- Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule • GlobeNewswire Inc. • 02/06/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 11:32:03 PM
- Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering • GlobeNewswire Inc. • 02/01/2024 09:22:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:37:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 03:46:33 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/29/2024 09:15:23 PM
- Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering • GlobeNewswire Inc. • 01/26/2024 02:04:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 01:35:27 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM